Aptose Biosciences Shares Set to Reverse Split on Wednesday, February 26th (NASDAQ:APTO)

Shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) are scheduled to reverse split on the morning of Wednesday, February 26th. The 1-30 reverse split was announced on Tuesday, February 18th. The number of shares owned by shareholders will be adjusted after the market closes on Tuesday, February 25th.

Aptose Biosciences Stock Performance

NASDAQ:APTO traded up $0.01 on Tuesday, reaching $0.19. The company’s stock had a trading volume of 4,882,723 shares, compared to its average volume of 5,252,953. Aptose Biosciences has a 1-year low of $0.13 and a 1-year high of $2.01. The business’s 50-day moving average price is $0.21 and its two-hundred day moving average price is $0.31. The firm has a market cap of $11.65 million, a PE ratio of -0.07 and a beta of 0.88.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $2.00 price objective on shares of Aptose Biosciences in a research report on Wednesday, February 12th. StockNews.com began coverage on shares of Aptose Biosciences in a report on Monday. They issued a “hold” rating for the company.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp raised its stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 75.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 703,384 shares of the biotechnology company’s stock after purchasing an additional 301,634 shares during the quarter. Sigma Planning Corp owned approximately 1.17% of Aptose Biosciences worth $158,000 at the end of the most recent reporting period. 26.62% of the stock is currently owned by institutional investors and hedge funds.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.